ARCUTIS BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 196.27K shares, a 921.11% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 140.67K shares, a 27.89% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 387.92K shares, a 13.70% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 196.99K shares, a 42.16% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 714.13K shares, a 10.02% increase from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 649.11K shares, a 86.44% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 348.17K shares, a 4.90% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 331.89K shares, a 29.11% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 196.27K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 921.85K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 140.67K shares 10-Q · filed 2026-05-06 | 744.80K shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 387.92K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 714.13K shares 10-K · filed 2026-02-25 |
| 2025-09-30 | 196.99K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | 667.39K shares derived: sum of 4 quarters · filed 2025-10-28 |
| 2025-06-30 | 19.22K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 608.97K shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 110.00K shares 10-Q · filed 2025-05-06 | 737.24K shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 341.19K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | 649.11K shares 10-K · filed 2025-02-25 |
| 2024-09-30 | 138.57K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 416.57K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 147.49K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 450.32K shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 21.86K shares 10-Q · filed 2024-05-14 | 338.54K shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 108.65K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 348.17K shares 10-K · filed 2024-02-27 |
| 2023-09-30 | 172.32K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | 280.54K shares derived: sum of 4 quarters · filed 2023-11-03 |
| 2023-06-30 | 35.70K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 239.04K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 31.50K shares 10-Q · filed 2023-05-09 | 260.45K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 41.02K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 331.89K shares 10-K · filed 2023-02-28 |
| 2022-09-30 | 130.82K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 344.03K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 57.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 243.51K shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 102.94K shares 10-Q · filed 2022-05-05 | 247.63K shares derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | 53.17K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | 257.06K shares 10-K · filed 2022-02-22 |
| 2021-09-30 | 30.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 249.19K shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 61.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 247.80K shares derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | 112.36K shares 10-Q · filed 2021-05-06 | 201.44K shares derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 45.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | 197.23K shares 10-K · filed 2021-02-16 |
| 2020-09-30 | 28.91K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | |
| 2020-06-30 | 14.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | |
| 2020-03-31 | 108.15K shares 10-Q · filed 2020-05-12 | |
| 2019-12-31 | 250.87K shares 10-K · filed 2021-02-16 | |
| 2018-12-31 | 918.88K shares 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |